Methods for treating obesity and/or metabolic syndrome
The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method for treating excessive weight or obesity or for treating metabolic syndrome or a symptom thereof, comprising administering an effective amount of a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom to a subject suffering from excessive weight or obesity or metabolic syndrome or a symptom thereof.
2. The method of claim 1 , comprising administering an amount of the population enriched for STRO-1 + cells and/or the progeny and/or the soluble factors sufficient to reduce body weight by at least about 3% about 4 weeks after the administration.
3. The method of claim 1 , wherein the symptom of metabolic syndrome is selected from the group consisting of elevated triglycerides, elevated low density lipoproteins, reduced high density lipoproteins, reduced lipoprotein index, elevated fasting glucose levels, elevated fasting insulin, reduced glucose clearance following feeding, insulin resistance, impaired glucose tolerance, obesity and combinations thereof.
4. The method of claim 1 , comprising administering an amount of the population enriched for STRO-1 + cells and/or the progeny and/or the soluble factors sufficient to result in one or more of the following:
(i) reduce triglycerides;
(ii) reduce low density lipoproteins;
(iii) increase high density lipoproteins;
(iv) increase lipoprotein index;
(v) reduce fasting glucose levels;
(vi) increase insulin secretion by the pancreas;
(vii) increase glucose clearance following feeding;
(viii) reduce insulin resistance; and
(ix) reduce body weight.
5. The method of claim 1 comprising administering a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.
6. The method of claim 1 , wherein the population enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom are administered systemically.
7. The method of claim 6 , wherein the population and/or the progeny and/or the soluble factors are administered a plurality of times.
8. The method of claim 7 , wherein the population and/or the progeny and/or the soluble factors are administered once every four or more weeks.
9. The method of claim 1 comprising administering a dose of the population enriched for STRO-1 + cells and/or the progeny and/or the soluble factors sufficient to achieve one or more of the following:
(i) reduce triglycerides;
(ii) reduce low density lipoproteins;
(iii) increase high density lipoproteins;
(iv) increase lipoprotein index;
(v) reduce fasting glucose levels;
(vi) increase insulin secretion by the pancreas;
(vii) increase glucose clearance following feeding;
(viii) reduce insulin resistance; and
(ix) reduce body weight.
10. The method of claim 1 , comprising administering between 0.1×10 6 to 5×10 6 STRO-1 + cells and/or progeny thereof per kg.
11. The method of claim 10 , comprising administering between 0.3×10 6 to 2×10 6 STRO-1 + cells and/or progeny thereof per kg.
12. The method of claim 1 comprising administering a low dose of STRO-1 + cells and/or progeny thereof.
13. The method of claim 12 , wherein the low dose of STRO-1 + cells and/or progeny thereof comprises between 0.1×10 5 and 0.5×10 6 STRO-1 + cells and/or progeny thereof per kg.
14. The method of claim 12 , wherein the low dose of STRO-1 + cells and/or progeny thereof comprises about 0.3×10 6 STRO-1 + cells and/or progeny thereof per kg.
15. The method of claim 1 , wherein the population enriched for STRO-1 + cells and/or progeny cells are autogeneic or allogeneic and/or the soluble factors can be derived from autogeneic or allogeneic cells.
16. The method of claim 1 , wherein the population enriched for STRO-1 + cells and/or progeny cells have been culture expanded prior to administration and/or prior to obtaining the soluble factors.
17. The method of claim 1 , wherein the population enriched for STRO-1 + cells are STRO-1 bri , and/or express tissue non-specific alkaline phosphatase (TNAP) and/or the progeny cells and/or soluble factors are derived from STRO-1 + cells that are STRO-1 bri and/or express TNAP.
18. The method of claim 1 , wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered in the form of a composition comprising said STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom and a carrier and/or excipient.